Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2007 Oct;9(5):439-46.

Lentivirus as a potent and mechanistically distinct vector for genetic immunization

Affiliations
Review

Lentivirus as a potent and mechanistically distinct vector for genetic immunization

Yukai He et al. Curr Opin Mol Ther. 2007 Oct.

Abstract

T-cell-mediated immunity is critical for the prevention and control of a broad range of infectious diseases and human malignancies. Genetic immunization is a promising approach for the elicitation of T-cell immunity. Recombinant lentivectors are now being developed and evaluated as antigen delivery platforms for genetic immunization and immune engineering. Early results from studies utilizing lentivectors are promising. Third generation lentivectors have been engineered to improve biosafety and reduce antivector immune responses. The ability of third generation lentivectors to efficiently transduce non-dividing cells, including dendritic cells, suggests important advantages over other antigen delivery platforms. Studies suggest that immunization with lentivectors induces remarkably potent and durable primary and memory T-cell immunity. The combination of skin-targeted immunization and potentially unique mechanisms of immune induction likely contribute to the potent immunogenicity observed. Taken together, this accumulating evidence supports the ongoing development and clinical translation of lentivector-based genetic immunization strategies.

PubMed Disclaimer

References

    1. Robinson HL, Amara RR. T cell vaccines for microbial infections. Nat Med. 2005;11:S25–32. - PubMed
    1. Autran B, Carcelain G, Combadiere B, Debre P. Therapeutic vaccines for chronic infections. Science. 2004;305:205–8. - PubMed
    1. Barouch DH, Nabel GJ. Adenovirus vector-based vaccines for human immunodeficiency virus type 1. Hum Gene Ther. 2005;16:149–56. - PubMed
    1. He Y, Zhang J, Mi Z, Robbins P, Falo LD., Jr Immunization with lentiviral vector-transduced dendritic cells induces strong and long-lasting T cell responses and therapeutic immunity. J Immunol. 2005;174:3808–17. - PubMed
    1. Collins MK, Cerundolo V. Gene therapy meets vaccine development. Trends Biotechnol. 2004;22:623–6. - PubMed

Publication types

LinkOut - more resources